News & Events
< Back to News Overview
Hatchtech's head lice product passes Phase I study
21 / 05 / 2007
DeOvoT, Hatchtech's head louse control product has completed its first human trials finding no side effects or other adverse events associated with the product. 32 patients were treated at escalating dose levels and carefully monitored via observation, blood tests and electrocardiography.
"Most other insecticidal products currently on market have not shown this level of human safety. We also believe that the DeOvoT product will eventually be the most effective anti-head lice product on the market despite some significant milestones still to come on our path to market," said Dr Paul MacLeman, CEO of Hatchtech.
"This is a big step forward and demonstrating safety also adds substantial value to our other product developments."
The trial was conducted by Q-Pharm in Queensland from February to April 2007.
Hatchtech intends to file an Investigational New Drug Application with the US Food and Drug Administration later in 2007 in preparation for a Phase II trial in an affected patient population in early 2008.
Hatchtech's crop protection product is currently undergoing boom-spray scale plant safety and efficacy studies in greenhouse trials at the South Australian Research and Development Institute, having demonstrated safety in screening mammalian toxicity tests late in 2006.
Further laboratory work towards new products continues in a range of other important veterinary, industrial and household pest species. Rising resistance levels in pest populations and concerns about safety continue to drive demand for new products in all these sectors.
"Most other insecticidal products currently on market have not shown this level of human safety. We also believe that the DeOvoT product will eventually be the most effective anti-head lice product on the market despite some significant milestones still to come on our path to market," said Dr Paul MacLeman, CEO of Hatchtech.
"This is a big step forward and demonstrating safety also adds substantial value to our other product developments."
The trial was conducted by Q-Pharm in Queensland from February to April 2007.
Hatchtech intends to file an Investigational New Drug Application with the US Food and Drug Administration later in 2007 in preparation for a Phase II trial in an affected patient population in early 2008.
Hatchtech's crop protection product is currently undergoing boom-spray scale plant safety and efficacy studies in greenhouse trials at the South Australian Research and Development Institute, having demonstrated safety in screening mammalian toxicity tests late in 2006.
Further laboratory work towards new products continues in a range of other important veterinary, industrial and household pest species. Rising resistance levels in pest populations and concerns about safety continue to drive demand for new products in all these sectors.